Home・Lista de Ações・Cogent Biosciences Inc

Cogent Biosciences Inc

Fechado

36.65 3.88

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

36.5

Máximo

36.89

Indicadores-chave
By Trading Economics
Rendimento	947K -96M
EPS	-0.52
Funcionários	258
EBITDA	537K -94M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+46.64% upside

Dividendos
By Acuity
Próximos Ganhos	2 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-69M 6.6B
Abertura anterior	32.77
Fecho anterior	36.65

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de ago. de 2026, 23:51 UTC

RBA Meeting Minutes Release on August 25, 2026, Sparks Cautious Market Sentiment Amid Persistent Inflation and Economic Cooling in Australia.

22 de ago. de 2026, 23:51 UTC

Macro News

Bitcoin is trading lower during Saturday's session, despite earlier rising above $70,000, amid ongoing geopolitical tensions and pressures in the bond market.

22 de ago. de 2026, 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields raise concerns over economic growth and investor sentiment shifts towards safer assets.

22 de ago. de 2026, 23:41 UTC

Cryptocurrency Prices Drop Amid Rising Bond Yields and Geopolitical Tensions, Impacting Market Sentiment.

22 de ago. de 2026, 23:41 UTC

Cryptocurrency Markets Decline Amid Rising Bond Yields and Economic Pressures, with Ethereum Down 3.9% and Bitcoin 1.7%.

22 de ago. de 2026, 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields and inflation concerns pressure risk assets amid mixed global market performance.

22 de ago. de 2026, 23:41 UTC

U.S. Goods Trade Balance Expected to Show $99 Billion Deficit Amidst Rising Tariff Tensions with Canada

22 de ago. de 2026, 23:41 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Expected to Impact Market Sentiment Amid Cautious Investor Outlook.

22 de ago. de 2026, 23:41 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% Amid Caution Over Economic Conditions and Market Volatility

22 de ago. de 2026, 23:41 UTC

Canada's Current Account Deficit Expected to Widen to -5.5 Billion CAD Amid Trade Negotiation Uncertainties with the U.S.

22 de ago. de 2026, 23:41 UTC

Terra is trading lower today, reversing three consecutive sessions of gains. The asset has declined significantly since Friday's close, with no specific news identified.

22 de ago. de 2026, 23:31 UTC

US GDP Price Index QoQ 2nd Estimate on August 26 Forecasts 0.063% Increase Amid Rising Oil Prices and Optimistic Q3 Growth Outlook

22 de ago. de 2026, 23:31 UTC

South Africa's Balance of Trade Data Set for Release Amidst Investor Optimism Following Recent Surplus Growth and Global Economic Pressures.

22 de ago. de 2026, 23:31 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Mixed Economic Sentiment and Market Volatility

22 de ago. de 2026, 23:21 UTC

Market braces for July 2026 PCE Price Index release, with a modest +0.1% increase forecast amid mixed inflation sentiment and external economic pressures.

22 de ago. de 2026, 23:21 UTC

PCE Price Index Release on August 26, 2026: Key Inflation Indicator Amid Market Volatility and Fed Policy Concerns.

22 de ago. de 2026, 23:21 UTC

U.S. Personal Income Expected to Rise 0.3% in August Amid Cautious Market Sentiment and Consumer Spending Concerns

22 de ago. de 2026, 23:21 UTC

U.S. Personal Spending Forecasted to Rise 0.2% in August Amid Mixed Economic Signals and Inflation Concerns

22 de ago. de 2026, 23:21 UTC

Core PCE Price Index MoM for July 2026 set to release on August 26, with a forecasted increase of 0.2%, amid rising oil prices and geopolitical tensions influencing market sentiment.

22 de ago. de 2026, 23:21 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.5% Amid Economic Caution and Upcoming Market Influences

22 de ago. de 2026, 23:21 UTC

U.S. Durable Goods Orders Expected to Rise 0.7% Amid Economic Volatility and Geopolitical Tensions, with Market Cautiously Optimistic Ahead of Jackson Hole Symposium

22 de ago. de 2026, 23:21 UTC

U.S. GDP Growth Rate Expected at +1.5% for Q2 2026 Amid Optimistic Economic Indicators and Fed's Revised Forecast of +2.3% for Q3

22 de ago. de 2026, 23:21 UTC

U.S. Corporate Profits Report for Q2 2026 Set to Release Amid Economic Uncertainty and Market Volatility on August 26.

22 de ago. de 2026, 23:11 UTC

ECB Meeting Accounts Set for Release Amid Market Anticipation of Interest Rate Signals and Inflation Trends on August 27, 2026.

22 de ago. de 2026, 23:11 UTC

Mexico's Trade Balance Expected to Show Continued Surplus Amid U.S.-Canada Negotiation Uncertainty Ahead of August 27 Data Release.

22 de ago. de 2026, 23:11 UTC

Brazil's Unemployment Rate Set for Release Amid Optimistic Market Sentiment Following June Drop to 5.4%

22 de ago. de 2026, 23:11 UTC

News

Ethereum is lower today, continuing a decline since Friday's close. Earlier, the asset reached a session low before recovering slightly.

22 de ago. de 2026, 23:11 UTC

Correlated Moves

Avalanche is declining today, influenced by a drop in correlated asset Ethereum. The asset's recent strong performance contrasts with today's downturn during the session.

22 de ago. de 2026, 23:11 UTC

News

Ethereum is lower during Saturday's session, reflecting a significant drop since Friday's close. The asset reached a session low earlier today.

22 de ago. de 2026, 23:01 UTC

Macro News

The DAX 30 Index is declining after the U.S. imposed 50% tariffs on Canadian goods, worsening trade relations and impacting investor sentiment.

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

46.64% parte superior

Previsão para 12 meses

Média 53.86 USD 46.64%

Máximo 60 USD

Mínimo 45 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.